Expectations for Anticipated Guideline Updates: Addressing Key Gaps in Ph+ ALL Care

Dr. Bijal Shah shares insights on anticipated updates to NCCN guidelines for Ph+ ALL, emphasizing key areas of focus to address gaps and advance patient care.

EP: 1.Guidelines as a Framework for Improved Outcomes in Ph+ ALL

EP: 2.Evolving Treatment Paradigms in Ph+ ALL

Now Viewing

EP: 3.Expectations for Anticipated Guideline Updates: Addressing Key Gaps in Ph+ ALL Care

EP: 4.Looking Ahead: Ph+ ALL in 2025 and Beyond

• What are your expectations for an upcoming NCCN guidelines update for Ph+ ALL, and what specific areas do you hope will be addressed?

Related Videos

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.

Related Content

Advertisement

July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 28th 2025

Long COVID More Common Among Socially Vulnerable Individuals

Brooke McCormick

Social risk factors significantly increase the likelihood of developing long COVID, highlighting the urgent need for equitable health care and support systems.

July 28th 2025

Gefurulimab for gMG Meets Key End Points in PREVAIL Trial

Marco Meglio

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.